• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    5/29/24 4:31:09 PM ET
    $A
    $ANL
    $GRTX
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $A alert in real time by email

    Gainers

    • OneMedNet (NASDAQ:ONMD) shares increased by 52.3% to $2.97 during Wednesday's after-market session. The company's market cap stands at $70.8 million.
    • Kintara Therapeutics (NASDAQ:KTRA) shares rose 19.85% to $0.33. The company's market cap stands at $18.0 million.
    • Galera Therapeutics (NASDAQ:GRTX) shares moved upwards by 9.69% to $0.21. The market value of their outstanding shares is at $11.6 million.
    • Petros Pharma (NASDAQ:PTPI) shares increased by 8.74% to $0.67. The company's market cap stands at $4.6 million.
    • Cue Health (NASDAQ:HLTH) stock moved upwards by 8.49% to $0.06. The company's market cap stands at $9.5 million.
    • Adlai Nortye (NASDAQ:ANL) stock rose 8.27% to $8.9. The market value of their outstanding shares is at $328.4 million.

    Losers

    • Onconetix (NASDAQ:ONCO) stock fell 18.6% to $0.24 during Wednesday's after-market session. The company's market cap stands at $5.3 million.
    • Agilent Technologies (NYSE:A) shares fell 13.33% to $126.1. The market value of their outstanding shares is at $36.9 billion. The company's, Q2 earnings came out today.
    • Immunovant (NASDAQ:IMVT) shares decreased by 8.7% to $27.0. The market value of their outstanding shares is at $3.9 billion.
    • Jin Medical International (NASDAQ:ZJYL) shares declined by 8.47% to $2.81. The market value of their outstanding shares is at $439.8 million.
    • Sonoma Pharmaceuticals (NASDAQ:SNOA) stock decreased by 7.7% to $0.24. The company's market cap stands at $3.7 million.
    • iSpecimen (NASDAQ:ISPC) stock fell 7.18% to $0.29. The market value of their outstanding shares is at $2.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $A alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $A
    $ANL
    $GRTX
    $HLTH

    CompanyDatePrice TargetRatingAnalyst
    Immunovant Inc.
    $IMVT
    3/20/2026$28.00Mkt Perform
    Bernstein
    Adlai Nortye Ltd.
    $ANL
    3/20/2026$23.00Outperform
    Leerink Partners
    Adlai Nortye Ltd.
    $ANL
    2/13/2026$16.00Neutral → Buy
    H.C. Wainwright
    Agilent Technologies Inc.
    $A
    1/20/2026$180.00Buy
    HSBC Securities
    Immunovant Inc.
    $IMVT
    1/6/2026$50.00Peer Perform → Outperform
    Wolfe Research
    Agilent Technologies Inc.
    $A
    1/5/2026$160.00In-line → Outperform
    Evercore ISI
    Agilent Technologies Inc.
    $A
    12/15/2025$165.00Equal Weight → Overweight
    Barclays
    Agilent Technologies Inc.
    $A
    12/9/2025$170.00Buy
    Goldman
    More analyst ratings

    $A
    $ANL
    $GRTX
    $HLTH
    SEC Filings

    View All

    Agilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    4/3/26 4:05:10 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 8-K filed by Galera Therapeutics Inc.

    8-K - Galera Therapeutics, Inc. (0001563577) (Filer)

    4/3/26 6:03:35 AM ET
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 425 filed by Onconetix Inc.

    425 - Onconetix, Inc. (0001782107) (Subject)

    4/2/26 8:31:13 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $A
    $ANL
    $GRTX
    $HLTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Roivant Sciences Ltd. bought $349,999,986 worth of shares (16,666,666 units at $21.00), increasing direct ownership by 17% to 113,317,007 units (SEC Form 4)

    4 - Immunovant, Inc. (0001764013) (Issuer)

    12/12/25 5:17:21 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Yu Jeffrey converted options into 2,307,549 shares, bought $959,586 worth of shares (2,010,479 units at $0.48) and was granted 245,000 shares, increasing direct ownership by 165% to 7,326,223 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:56:08 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Medical Officer Yu Jeffrey bought $8,929 worth of shares (9,540 units at $0.94) and was granted 230,769 shares, increasing direct ownership by 10% to 2,763,195 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:55:32 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $A
    $ANL
    $GRTX
    $HLTH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $ANL
    $GRTX
    $HLTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Venker Eric

    4 - Immunovant, Inc. (0001764013) (Issuer)

    4/3/26 4:33:01 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Henson Meghan

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    4/2/26 4:06:44 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 3 filed by new insider White David Allan

    3 - Onconetix, Inc. (0001782107) (Issuer)

    3/27/26 4:10:42 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $A
    $ANL
    $GRTX
    $HLTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bernstein initiated coverage on Immunovant Sciences with a new price target

    Bernstein initiated coverage of Immunovant Sciences with a rating of Mkt Perform and set a new price target of $28.00

    3/20/26 8:36:14 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Leerink Partners initiated coverage on Adlai Nortye Ltd. with a new price target

    Leerink Partners initiated coverage of Adlai Nortye Ltd. with a rating of Outperform and set a new price target of $23.00

    3/20/26 8:35:32 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adlai Nortye Ltd. upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Adlai Nortye Ltd. from Neutral to Buy and set a new price target of $16.00

    2/13/26 9:51:23 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $A
    $ANL
    $GRTX
    $HLTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update

    Realbotix Announces Expected Delivery of 19 Robots in March, April, and May 2026 as it Scales Production Capacity; Onconetix recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a subsidiary of Realbotix Corp. CINCINNATI, Ohio, April 02, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC ("Realbotix"), the target of Onconetix's previously announced pending acquisition. On April 1, 2026, Realbotix announced that it expects to deliver 19 previously ordered robots and corresponding AI implementations for months of March, April, and

    4/2/26 8:30:00 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

    Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated greater levels of proptosis improvement from baseline after the initial 12-week high-dose period than after the following 12-week low-dose period, supporting the benefit of deeper IgG suppression. The hyperthyroid patients in the TED studies showed similar response rates of thyroid hormone normalization to those seen in the batoclimab Phase 2 study in Graves' diseaseImmunovant remains focused on rapid advancement of IMVT-1402 in multiple indications DURHAM, N.C., April 02, 2026 (GLOBE NEWSWIRE)

    4/2/26 5:00:00 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OneMedNet, Onco-Innovations and Inka Health Announces Collaboration Aimed to Accelerate Potential for Oncology Drug Development Using Real-World Data and AI

    MINNEAPOLIS, April 01, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) (the "OneMedNet," the "Company," "we," "us" or "our"), a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD), is pleased to announce that Inka Health, a wholly-owned subsidiary of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has entered into a collaboration with OneMedNet Inc., under which Onco-Innovations and Inka Health will have access to OneMedNet's iRWD™ platform— powered by Palantir (PLTR) Foundry— providing it access to U.S. real-world oncology data. The agreement is intended to accelerate development timelines, reduce clinical and re

    4/1/26 8:55:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $A
    $ANL
    $GRTX
    $HLTH
    Leadership Updates

    Live Leadership Updates

    View All

    Agilent Names Adam S. Elinoff as Chief Financial Officer

    Agilent Technologies Inc. (NYSE:A) today announced the appointment of Adam S. Elinoff as chief financial officer, effective Nov. 17. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027719923/en/Adam S. Elinoff, Chief Financial Officer, Agilent Technologies Elinoff brings two decades of financial experience spanning corporate finance, investor relations, strategy and business transformation, and has a proven record of driving enterprise-wide transformations, optimizing financial operations and scaling global capabilities. He joins Agilent from Amgen, a worldwide pioneer in biotechnology, where he advanced through a series of

    10/27/25 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025

    Agilent Technologies Inc. (NYSE:A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions that enable simultaneous DNA and methylation profiling from a single sample, the Avida product portfolio has expanded to include three new DNA panels*. Optimized based on the requirements of the European OncNGS Consortium, these catalog p

    4/24/25 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Dr. Kenneth Alleyne Joins OneMedNet Board of Directors

    MINNEAPOLIS, March 03, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet"), the leading Real World Data platform powered by AI-driven de-identification, announces the appointment of Dr. Kenneth Alleyne to its Board of Directors. A board-certified orthopedic surgeon specializing in sports medicine, Dr. Alleyne will assume the role of Chair of the Audit Committee, bringing extensive expertise in healthcare, insurance, investment, and corporate governance to the organization. Dr. Alleyne is the managing partner of HartHaven Partners, a healthcare consulting firm supporting private equity and venture capital firms. He co-founded NextLevel Health Partners and Zing Health

    3/3/25 8:35:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $A
    $ANL
    $GRTX
    $HLTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Petros Pharmaceuticals Inc.

    SC 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    11/14/24 5:17:37 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Onconetix Inc.

    SC 13G - Onconetix, Inc. (0001782107) (Subject)

    11/14/24 11:19:35 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Petros Pharmaceuticals Inc.

    SC 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    11/13/24 11:14:05 AM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $A
    $ANL
    $GRTX
    $HLTH
    Financials

    Live finance-specific insights

    View All

    Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

    Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated greater levels of proptosis improvement from baseline after the initial 12-week high-dose period than after the following 12-week low-dose period, supporting the benefit of deeper IgG suppression. The hyperthyroid patients in the TED studies showed similar response rates of thyroid hormone normalization to those seen in the batoclimab Phase 2 study in Graves' diseaseImmunovant remains focused on rapid advancement of IMVT-1402 in multiple indications DURHAM, N.C., April 02, 2026 (GLOBE NEWSWIRE)

    4/2/26 5:00:00 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Agilent Reports First-Quarter Fiscal Year 2026 Financial Results

    Delivers solid Q1 results, raises FY26 reported revenue outlook and increases non-GAAP EPS(3) guidance while confirming core-revenue growth(1) and margin expansion First-quarter fiscal year 2026 Revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% on a core(1) basis compared with the first quarter of 2025. GAAP net income of $305 million; earnings per share (EPS) of $1.07, a decline of 4% from the first quarter of 2025. Non-GAAP(2) net income of $386 million; non-GAAP EPS(3) of $1.36, growing 4% from the first quarter of 2025. Fiscal year 2026 and second-quarter outlook Fiscal year 2026 revenue is expected in t

    2/25/26 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Announces Cash Dividend of 25.5 Cents per Share

    Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide t

    2/11/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials